MedTrace Logo

Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism

NCT06465108 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-03-20

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism.

Conditions

  • Hypoparathyroidism

Interventions

DRUG

MBX 2109

Supplied as 1.5 mg per vial reconstituted in 1.4 mL water for injection to a concentration of 1.0 mg/mL

OTHER

Placebo

Supplied in 1.4 mL water for injection

Sponsors & Collaborators

  • MBX Biosciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-08
Primary Completion
2025-05-23
Completion
2025-06-04
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06465108 on ClinicalTrials.gov